(European Association for the Study of the Liver) Thalidomide has shown potential to be used as the first adjuvant therapy for hepatocellular carcinoma, according to data presented at the International Liver Congress 2011.

Berlin, Germany, Saturday 02 April 2011: Thalidomide has shown potential to be used as the first adjuvant therapy for hepatocellular carcinoma (HCC), according to data presented at the International Liver CongressTM 2011.1 A new study found thalidomide gave HCC patients who'd undergone grossly curative resection ...

In draft guidance published today (26 August 2010) NICE has recommended two treatments for multiple myeloma. Thalidomide (Thalidomide, Celgene) in combination with an alkylating agent and a corticosteroid is recommended for the first-line treatment of multiple myeloma in people for whom high-dose chemotherapy with stem cell transplantation is considered inappropriate. ...

Seventy-seven countries do not have a blood donation rate high enough to meet "the basic needs for blood transfusions," the Associated Press reports. The WHO released new global data on blood donation for World Blood Donor Day on June 14. "[H]alf of the global blood donations are collected in developed ...

Thalidomide was once a dreaded name in the Pharmaceutical industry. It was initially marketed in some European countries nearly 5 decades back as a sedative and after millions of pregnant women took it for morning sickness it had devastating results on the babies. The babies were born with flippers instead ...

Thalidomide, the sedative blamed for tragic birth defects half a century ago, treated a rare inherited blood disorder, according to lab experiments reported on Sunday.

Japanese scientists have uncovered how thalidomide led to deformities in children born to mothers taking the drug in the 1950s and 1960s, according to a study released Friday.

Research into the controversial drug thalidomide reveals that the mechanism through which the drug causes limb defects is the same process which causes it to damage internal organs and other tissues.

Research into the controversial drug thalidomide reveals that the mechanism through which the drug causes limb defects is the same process which causes it to damage internal organs and other tissues. The article, published in Bio-Essays, outlines the challenges surrounding thalidomide research and claims that confirmation of a 'common mechanism' ...

Research into the controversial drug thalidomide reveals that the mechanism through which the drug causes limb defects is the same process which causes it to damage internal organs and other tissues. The article, published in Bio-Essays , outlines the challenges surrounding thalidomide research and claims that confirmation of ...

Resurgence of thalidomide use in Africa and South America raises the urgent need to isolate the negative side effects by identifying the drug's "common mechanism."